A
Antheia
Their mission is to make & fairly provide Medicines to all
About Antheia
Antheia is a science and technology company focused on developing next-generation plant-inspired medicines. By leveraging synthetic biology, genomics, informatics, and fermentation, Antheia harnesses beneficial molecules from plants to create active pharmaceutical ingredients (APIs) in more controlled and economical ways. The company aims to disrupt the traditional agriculture-based supply chain, creating more equitable distribution channels and accelerating the discovery of new medicines. Antheia serves pharmaceutical companies and operates in the biotechnology and pharmaceutical markets. Its business model revolves around the development and sale of APIs, making money through partnerships, licensing agreements, and direct sales.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Menlo Park, United States
- Employees
- 66
- Open positions
- 5
- Dealroom signal
- 85.3/100
- Industry
- Health, Real Estate
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Supply Chain Management, Intellectual Property, Biotechnology, Synthetic Biology, Spinout, Biotech and Pharma, Woman Founder, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Antheia.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Jan 2026 | $0 | — | Undisclosed | ↗ |
| SERIES COther financing | Jan 2026 | $24M | $365M | Global Health Investment Corporation · ATHOS Venture · America's Frontier Fund · EDBI | ↗ |
Growth signals
Latest recorded traffic for Antheia is 6.1K monthly website visits, up 13% over the last three months. Antheia's team grew 1.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
US National Science Foundation
In-Q-Tel
Echo Investment Capital
BioMaP Consortium
Series A3 investors entered at this stage
Viking Global Investors
Sherpalo Ventures
Hillspire
Series B and later7 investors entered at this stage
Oxford Finance
EDBI
Global Health Investment Corporation
S-Cubed Capital
Civilization Ventures- AVATHOS Venture
America's Frontier Fund
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Antheia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Antheia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







